Modality
Nanobody
MOA
EGFRi
Target
GIP-R
Pathway
Apoptosis
CKDHeart FailureHuntington's
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
~Apr 2017
→ ~Jul 2018
Phase 2
Oct 2018
→ Jul 2030
Phase 2Current
NCT07866206
2,505 pts·CKD
2025-12→TBD·Terminated
NCT08229380
2,368 pts·Heart Failure
2018-10→2030-07·Recruiting
4,873 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-07-234.3y awayPh3 Readout· Heart Failure
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Recruit…
P2/3
Termina…
Catalysts
Ph3 Readout
2030-07-23 · 4.3y away
Heart Failure
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07866206 | Phase 2/3 | CKD | Terminated | 2505 | 6MWD |
| NCT08229380 | Phase 2/3 | Heart Failure | Recruiting | 2368 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| 207-2754 | Samsung Biologics | Phase 1/2 | KRASG12D | |
| Mavuratamab | Blueprint Medicines | NDA/BLA | BET |